INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3-5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy of cannabinoids in extending the survival and slowing of disease progression in animal models with ALS. There are anecdotal reports of cannabis slowing disease progression in persons with ALS (pALS) and that cannabis alleviated the symptoms of spasticity and pain. However, a clinical trial in pALS with these objectives has not been conducted. METHODS AND ANALYSIS: The Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease trial is a randomised, double-blind, placebo-controlled cannabis trial in pALS conducted at the Gold Coast University Hospital, Australia. The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration. A total of 30 pALS with probable or definite ALS diagnosis based on the El Escorial criteria, with a symptom duration of <2 years, age between 25 and 75years and with at least 70% forced vital capacity (FVC) will be treated for 6 months. The primary objective of the study is to evaluate the efficacy of CBME compared with placebo in slowing the disease progression measured by differences in mean ALS Functional Rating Scale-Revised and FVC score between the groups at the end of treatment. The secondary objectives are to evaluate the safety and tolerability of CBME by summarising adverse events, the effects of CBME on spasticity, pain, weight loss and quality of life assessed by the differences in mean Numeric Rating Scale for spasticity and Numeric Rating Scale for pain, percentage of total weight loss and ALS specific quality of life-Revised questionnaire. ETHICS AND DISSEMINATION: The study has been approved by the local Institutional Review Board. The results of this study will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03690791.

International Cannabis and Cannabinoids Institute Prague Czech Republic

Neurology Gold Coast Hospital and Health Service Southport Queensland Australia

School of Medicine Duke University Durham North Carolina USA

School of Medicine Griffith University Gold Coast Queensland Australia

Zobrazit více v PubMed

Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942–55. 10.1016/S0140-6736(10)61156-7 PubMed DOI

Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 2015;6:171 10.4103/2152-7806.169561 PubMed DOI PMC

Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310–23. 10.3109/17482960802566824 PubMed DOI PMC

Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 2015;7:181–93. 10.2147/CLEP.S37505 PubMed DOI PMC

Brown RH, Al-Chalabi A, Sclerosis AL. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162–72. 10.1056/NEJMra1603471 PubMed DOI

Turner MR, Bowser R, Bruijn L, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:19–32. 10.3109/21678421.2013.778554 PubMed DOI PMC

Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001;18:264–70. 10.1177/104990910101800411 PubMed DOI

Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004;141:775–85. 10.1038/sj.bjp.0705667 PubMed DOI PMC

Sinclair J. An introduction to cannabis and the endocannabinoid system. Australian Journal of Herbal Medicine 2016;28:107–25.

De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009;23:1–15. 10.1016/j.beem.2008.10.013 PubMed DOI

Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010;160:480–98. 10.1111/j.1476-5381.2010.00735.x PubMed DOI PMC

Bilsland LG, Dick JRT, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006;20:1003–5. 10.1096/fj.05-4743fje PubMed DOI

Witting A, Weydt P, Hong S, et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 2004;89:1555–7. 10.1111/j.1471-4159.2004.02544.x PubMed DOI

Kim K, Moore DH, Makriyannis A, et al. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006;542:100–5. 10.1016/j.ejphar.2006.05.025 PubMed DOI

Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33–9. 10.1080/14660820310016813 PubMed DOI

Shoemaker JL, Seely KA, Reed RL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101:87–98. 10.1111/j.1471-4159.2006.04346.x PubMed DOI PMC

Weydt P, Hong S, Witting A, et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:182–4. 10.1080/14660820510030149 PubMed DOI

Laaris N, Good CH, Lupica CR. Δ9-Tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 2010;59:121–7. 10.1016/j.neuropharm.2010.04.013 PubMed DOI PMC

Ramirez BG, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904–13. 10.1523/JNEUROSCI.4540-04.2005 PubMed DOI PMC

ALSUntangled Group ALSUntangled No. 16: cannabis. Amyotroph Lateral Scler 2012;13:400–4. 10.3109/17482968.2012.687264 PubMed DOI

Espejo-Porras F, Piscitelli F, Verde R, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol 2015;10:233–44. 10.1007/s11481-015-9602-4 PubMed DOI

Amtmann D, Weydt P, Johnson KL, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95–104. 10.1177/104990910402100206 PubMed DOI

Gelinas D, Miller RG, Abood ME. A pilot study of safety and tolerability of delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3.

Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 2010;81:1135–40. 10.1136/jnnp.2009.200642 PubMed DOI

Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (canals): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019;18:155–64. 10.1016/S1474-4422(18)30406-X PubMed DOI

Carter GT, Abood ME, Aggarwal SK, et al. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 2010;27:347–56. 10.1177/1049909110369531 PubMed DOI

Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 2011;106:2195–203. 10.1111/j.1360-0443.2011.03574.x PubMed DOI

Gonzalez R, Schuster RM, Mermelstein RJ, et al. Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol 2012;34:962–76. 10.1080/13803395.2012.703642 PubMed DOI PMC

Urbi B, Owusu MA, Hughes I, et al. Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta‐analysis. J Neurochem 2019;149:284–97. 10.1111/jnc.14639 PubMed DOI

Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, et al. Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1 PubMed DOI PMC

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:1344–64. 10.1111/j.1476-5381.2011.01238.x PubMed DOI PMC

Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012;2:241–54. 10.1177/2045125312457586 PubMed DOI PMC

Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802. 10.1111/epi.12631 PubMed DOI PMC

Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals 2012;5:529–52. 10.3390/ph5050529 PubMed DOI PMC

Queensland Health Clinical guidance: for the use of medicinal cannabis products in Queensland, 2017. Available: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf

Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol 2016;7 10.3389/fphar.2016.00309 PubMed DOI PMC

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 2018;49:12–19. 10.1016/j.ejim.2018.01.004 PubMed DOI

Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69:1135–47. 10.1007/s00228-012-1441-0 PubMed DOI

Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–12. 10.1016/S1474-4422(17)30115-1 PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03690791